Mucosal factors inducing neutrophil movement in ulcerative colitis: The role of interleukin 8 and leukotriene β4

Gut

Volumn 39, Issue 2, 1996, Pages 248-254

  Cole, A T ^a   Pilkington, B J ^a   McLaughlan, J ^a   Smith, C ^a   Balsitis, M ^a   Hawkey, C J ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Colonic mucosa; Interleukin 8; Leukotriene B4; Neutrophils; Ulcerative colitis

Indexed keywords

7 [3 (4 ACETYL 3 METHOXY 2 PROPYLPHENOXY)PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 CARBOXYLIC ACID; INTERLEUKIN 8; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CELL MIGRATION; CLINICAL ARTICLE; COLON MUCOSA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0029795918     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.39.2.248     Document Type: Article

References (28)

1. Saverymuttu SH, Chadwick VS, Hodgson HJ. Granulocyte migration in ulcerative colitis. Eur J Clin Invest 1985; 15: 60-3.
2. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin-8, a novel cytokine that activates neutrophils. J Clin Invest 1989; 84: 1045-9.
3. 4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood 1981; 58: 658-61.
4. Bazzoni F, Cassatella MA, Rossi F, Ceska M, Dewald B, Baggiolini M. Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin-8. J Exp Med 1991; 173: 771-4.
5. Mahida YR, Ceska M, Effenberger F, Kurlak L, Lindley I, Hawkey CJ. Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis. Clin Sci 1992; 82: 273-5.
6. Lobos EA, Sharon P, Stenson WF. Chemotactic activity in inflammatory bowel disease. Dig Dis Sci 1987; 32: 1380-8.
7. Chadwick VS, Schlup MMI, Cooper BT, Broom MF. Enzymes degrading bacterial chemotactic Fmet peptides in human ileal and colonic mucosa. J Gastroenterol Hepatol 1990; 5: 375-81.
8. Goldin E, Karmeli F, Selinger Z, Rachmilewitz D. Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation. Dig Dis Sci 1989; 34: 754-7.
9. Goldman G, Welboum R, Klausner JM, Kobzik L, Valeri CR, Shepro D, et al. Neutrophil accumulations due to pulmonary thromboxane synthesis mediate acid aspiration injury. J Appl Physiol 1991; 70: 1511-7.
10. Vilaseca J, Salas A, Guarner F, Rodriguez R, Malagelada JR. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology 1990; 98: 269-77.
11. Wilkinson PC. Leucocyte chemotaxis a perspective. In: Armitage JP, Lackie JM, eds. Biology of the chemotactic response. Cambridge: Cambridge University Press, 1990: 323-46.
12. Jenkins D, Goodall A, Scott BB. Ulcerative colitis: one disease or two (quantitative histological differences between distal and extensive disease). Gut 1990; 31: 426-30.
13. Seldenrijk CA, Morson BC, Meuwissen SGM, Schipper NW, Lindeman J, Meijer CJLM. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. Gut 1991; 32: 1514-20.
14. 4-stimulated human neutrophil functions. Prostaglandins 1989; 38: 655-74.
15. Haston WS, Shields JM. Neutrophil leucocyte chemotaxis: a simplified assay for measuring polarising responses to chemotactic factors. J Immunol Methods 1985; 81: 229-37.
16. Watson S, Abbott A. TiPS receptor nomenclature supplement. Trends Pharmacol Sci 1991; 12: S1-36.
17. Cole AT, Slater K, Sokal M, Hawkey CJ. In-vivo rectal inflammatory mediator changes with radiotherapy to the pelvis. Gut 1993; 34: 1210-4.
18. Powell WS. Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica. Prostaglandins 1980; 20: 947-57.
19. 4. Gastroenterology 1993; 104: A684.
20. McCarthy DA, Rampton DS, Liu YC. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991; 86: 489-93.
21. 4 synthesis in vitro in inflammatory bowel disease: inhibition by selective 5-LO inhibitor BWA4C. Gut 1992; 33: 513-7.
22. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis and Clostridium difficile colitis. Gastroenterology 1988; 95: 11-7.
23. Goldman G, Welbourn R, Valeri CR, Shepro D, Hechtman HB. Thromboxane A2 induces leukotnene B4 synthesis that in turn mediates neutrophil diapedesis via CD-18 activation. Microvasc Res 1991; 41: 367-75.
24. Ninnemann JL. Prostaglandins, leukotrienes and the immune response. Cambridge: Cambridge University Press, 1988.
25. Gimbrone MA, Obin MS, Brock AF, Luis EA, Hass PE, Hebert CA, et al. Endothelial interleukin-8. A novel inhibitor of leukocyte-endothelial interactions. Science 1989; 214: 1601-3.
26. 4 and neutrophil attractant/activation protein (interleukin-8) sequentially in response to stimulation with lipopolysaccharide and zymosan. J Clin Invest 1990; 86: 1556-64.
27. 4 potentiates colonic ulceration in the rat. Dig Dis Sci 1990; 35: 622-7.
28. Cole AT, Garlick NM, Galvin A, Robins A, Hawkey CJ. Rectal dialysis bioactivity in the absence of faeces. Gut 1995; 37 (suppl 2): A15.